This survey seems flawed. It’s a survey of 1,000 insured and 1,000 uninsured, but the rate of insured in the US is closer to 90-95%. The uninsured use cheap gen

This survey seems flawed. It’s a survey of 1,000 insured and 1,000 uninsured, but the rate of insured in the US is closer to 90-95%. The uninsured use cheap generics and manufacturer’s discount cards. There doesn’t seem to be a control for the type of insurance. Typical copay for insulin are in the range of $10-50/mo. 80% credit card use sounds like American consumer finance behavior across the board, whether to defer payment or earn points. Accumulating an average debt of $9,000 solely from insulin would be difficult to accomplish given the high insurance rate, and difficult to separate from other debt and report (plus there appears not to be a control for personal finance ability and circumstance.) There are serious initiatives and legislation to provide cheap, high quality generic insulin and monitoring tools, that don’t need help from counterproductive, bad statistics.